Q-omics provides the consensus-scored NTN3 profile across patient tissues and cancer cell-line models. NTN3 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, NTN3 is differentially expressed in 10, with the highest sampling consensus in THCA. Additionally, NTN3 RNA expression shows 18,657 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UCS, THCA, and TGCT as cancer lineages where NTN3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NTN3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NTN3 survival associations across molecular data types. NTN3 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NTN3 RNA expression–survival associations across cancer types. High NTN3 expression shows unfavorable associations in KIRP, ACC, KIRC and BLCA, but favorable associations in UCS and SCLC. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCS as the clearest survival context for NTN3 RNA expression.
This table summarizes NTN3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for NTN3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NTN3 shows lower tumor expression in THCA and KIRP and higher tumor expression in LUSC, KICH, COAD and BLCA. The THCA box plot shows higher NTN3 RNA expression in normal versus tumor tissue (log2 FC = −0.357, t-test p < 0.001).
This table shows molecular features associated with NTN3 in patient tissues and cancer cell lines. In patient samples, NTN3 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, NTN3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in BONE and BLOOD_Leukemia.
